Table 1.
A list of liposome-based delivery systems of CUR on cancer
| Cancer type | Trial | Influential effect | Ref |
|---|---|---|---|
| Lung cancer | CUR liposomes effect on Lewis lung carcinoma LL/2 cell in mice | Made LL/2 cells stagnate in G2/M phase | 104 |
| CUR-PEG-PEI liposomes on A549 cells | Enhanced cell delivery Better anticancer effect |
86 | |
| β-CD-CUR liposomes effect on A549 cells | Improved inhibition effect | 105 | |
| CUR with cholesterol-based cationic liposomes on A549 cells | Higher cytotoxicity Lower adverse effects |
106 | |
| Cervical cancer | CUR-loaded cationic liposomes on Hela and SiHa cells | Increase cell apoptosis More cytotoxicity |
113 |
| CUR-loaded CMD liposomes on Hela cells | Enhanced stability and cell delivery Protected from leak and longer retention time Stronger cytotoxicity |
114 | |
| Prostate cancer | CUR liposomes in PC-3 human prostate cancer cells | Promoted drug uptake Higher inhibition with concentration- and time-dependence Had targeting activity |
121 |
| CUR nanoliposomes on LNCaP and C4-2B cells | Improved the bioavailability and anticancer effect | 122 | |
| CUR liposomes with resveratrol effect on male B6C3F1/J mice | Improved CUR level in serum and prostate tissues Inhibited cell growth and induced apoptosis |
123 | |
| Breast cancer | CUR nanoliposomes on MCF-7 cells | Inhibited cell cycle arrest and induced apoptosis with dose-dependence Enhanced bioavailability |
78 |
| CUR-γ-CD liposomes on MCF-7 cells | Higher anti-tumor activity Lower adverse effects |
128 | |
| Osteosarcoma | CUR nanoliposomes with C6 ceramide on KHOS cells | Induced G2/M arrest Enhanced cytotoxic effect |
133 |
| CUR-γ-CD liposomes on KHOS cells | More uptake Promoted effectivity |
128 | |
| Liver cancer | CUR liposomes on Bel-7402 cells | Better inhibited cell proliferation and induced apoptosis | 139 |
| CUR cationic liposomes on HepG2 cells | Exhibited higher cytotoxicity | 106 |
Abbreviations: CUR, curcumin; CD, cyclodextrin; CMD, carboxymethyl dextran.